Director Mark Kaye converts 152 RSUs at CONMED (NYSE: CNMD) into stock

Q: What did CONMED Corp (CNMD) director Mark Kaye report in this Form 4?

Director Mark Kaye reported acquiring 152 shares of CONMED common stock on February 24, 2026 , through the exercise and conversion of 152 restricted stock units (RSUs) granted under the company’s non-employee director equity compensation plan.

Q: How many CONMED (CNMD) RSUs did Mark Kaye convert to common stock?

Mark Kaye converted 152 RSUs into 152 shares of CONMED common stock. Each RSU represents a contingent right to receive one common share, subject to the terms and conditions of CONMED’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.

Q: What are the vesting terms of the CONMED (CNMD) RSUs reported by Mark Kaye?

The reported RSUs generally vest 100% after a one-year period . According to the plan terms, the RSUs also vest immediately upon termination of the director’s service, making them fully deliverable as common stock if the director leaves the board.

Q: What equity plan governs the RSUs held by CONMED (CNMD) director Mark Kaye?

The RSUs are issued under CONMED’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan . This plan sets the terms for non-employee director equity awards, including RSU vesting schedules and the conversion of RSUs into shares of common stock.

Q: How many CONMED (CNMD) shares does Mark Kaye hold after this Form 4 transaction?

Following the RSU conversion, Mark Kaye directly owns 152 shares of CONMED common stock. The Form 4 indicates this share balance as the total held directly after completing the derivative exercise and resulting issuance of common stock.

Q: Was the CONMED (CNMD) Form 4 a market buy or sell by Mark Kaye?

No, the Form 4 reflects a derivative exercise/conversion , not an open market buy or sell. Code M indicates the exercise of RSUs into common stock, with no reported market purchase or sale transaction in this filing.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CONMED Corp director Mark Kaye reported acquiring 152 shares of common stock through the exercise and conversion of 152 RSUs on February 24, 2026. Each RSU represents a right to receive one share of common stock under the company’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.

The RSUs generally vest 100% after one year, with vesting accelerated immediately if the director’s service terminates. After this transaction, Kaye directly holds 152 shares of CONMED common stock.

Insider Trade Summary

152 shares exercised/converted

Mixed 2 txns

Insider Kaye Mark

Role Director

Type	Security	Shares	Price	Value
Exercise	RSUs (Restricted Stock Units)	152	$0.00	--
Exercise	Common Stock	152	$0.00	--

Holdings After Transaction: RSUs (Restricted Stock Units) — 0 shares (Direct); Common Stock — 152 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

02/26/2026 - 09:23 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Mark

(Last)

(First)

(Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO

33773

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/24/2026		M		152	A	$0	152	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
RSUs (Restricted Stock Units)	$0	02/24/2026		M			152	02/24/2026⁽¹⁾	02/24/2035	Common Stock	152	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period with the RSU vesting immediately upon termination of the Director's service.

	/s/ Thomas Fistek for Mark Kaye by Power of Attorney	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CONMED Corp (CNMD) director Mark Kaye report in this Form 4?

Director Mark Kaye reported acquiring 152 shares of CONMED common stock on February 24, 2026, through the exercise and conversion of 152 restricted stock units (RSUs) granted under the company’s non-employee director equity compensation plan.

How many CONMED (CNMD) RSUs did Mark Kaye convert to common stock?

Mark Kaye converted 152 RSUs into 152 shares of CONMED common stock. Each RSU represents a contingent right to receive one common share, subject to the terms and conditions of CONMED’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan.

What are the vesting terms of the CONMED (CNMD) RSUs reported by Mark Kaye?

The reported RSUs generally vest 100% after a one-year period. According to the plan terms, the RSUs also vest immediately upon termination of the director’s service, making them fully deliverable as common stock if the director leaves the board.

What equity plan governs the RSUs held by CONMED (CNMD) director Mark Kaye?

The RSUs are issued under CONMED’s 2020 Amended and Restated Non-Employee Director Equity Compensation Plan. This plan sets the terms for non-employee director equity awards, including RSU vesting schedules and the conversion of RSUs into shares of common stock.

How many CONMED (CNMD) shares does Mark Kaye hold after this Form 4 transaction?

Following the RSU conversion, Mark Kaye directly owns 152 shares of CONMED common stock. The Form 4 indicates this share balance as the total held directly after completing the derivative exercise and resulting issuance of common stock.

Was the CONMED (CNMD) Form 4 a market buy or sell by Mark Kaye?

No, the Form 4 reflects a derivative exercise/conversion, not an open market buy or sell. Code M indicates the exercise of RSUs into common stock, with no reported market purchase or sale transaction in this filing.